

Author Correction: LncRNA CASC2 inhibits cell proliferation, metastasis and EMT through miR-18a/SOCS5 axis in cholangiocarcinoma

L. PENG, Y.-H. LIU, S. NIE, M. GAO

Department of Pediatrics, The First Hospital of Jilin University, Changchun City, Jilin Province, China

Correction to: European Review for Medical and Pharmacological Sciences 2020; 24 (16): 8367-8376–DOI: 10.26355/eurrev_202008_22633–PMID: 32894543, published online 31 August, 2020.

The authors state that “the segment of Figure 2C (si-RNA-NC) was used twice due to a careless mistake during the preparation of Figure 2”.

The Publisher apologizes for any inconvenience this may cause.

The correct section is reproduced below.




Figure 2. CASC2 affects the proliferation of CCA cells in vitro. **A-D**, Clone formation assay shows the proliferation ability of QBC939 cells transfected with LV-CASC2 and LV-control or HUCCT1 cells transfected with siRNA-CASC2 and siRNA-NC. (magnification: 40×) **E-F**, CCK-8 assays show the proliferation ability of QBC939 cells transfected with LV-CASC2 and LV-control or HUCCT1 cells transfected with siRNA-CASC2 and siRNA-NC. ** $p < 0.01$, * $p < 0.05$ compared to control group.